 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Three months after its debut on the exchanges on May 9, the stock has scaled over 30 percent and analysts say there is room for an upside.

Mankind Pharma: Focus on Bharat, strong brand recall to help outperformance

The drugmaker's net profit surged 66.4 percent YoY to Rs 486.9 crore. The strong performance was aided by an industry-beating growth in the pharma segment

Mankind Pharma soars 9% as investors cheer stellar Q1 earnings

Recently listed Mankind Pharma surged over 30 percent on listing day from its price band while Ikio Lighting Ltd shares debuted over 56 percent premium from its issue price

Surge in grey market premium shows rising interest in public issues

While its attractive pricing has slightly narrowed, the brokerage firm has said that Mankind Pharma's products are still priced at a 21 percent discount to major rivals

Mankind Pharma gains as Kotak initiates coverage with 'add' call

The stock has delivered 37-percent returns since its listing in May 2023, the brokerage firm highlighted while adding that Mankind Pharma is one of the fastest growing domestic pharmaceutical companies with a leadership in value.

Mankind Pharma hits 52-week high, JP Morgan starts coverage with 'overweight' rating

ICICI Prudential Life, Kotak Life, Tata AIA Life, HDFC Life and SBI Life added at least one healthcare stock to their portfolios in May while raising stakes in several others.

Top life insurers turn bullish on healthcare stocks; investments higher than sector weightage in Nifty 100

Mankind Pharma Consolidated March 2023 Net Sales at Rs 2,052.67 crore, up 18.94% Y-o-Y

The firm reported a 52-percent increase in consolidated net profit at Rs 294 crore for the March quarter, aided by robust sales. Revenue rose to Rs 2,053 crore from Rs 1,726 crore in the year-ago period.

Antique cuts Mankind's target price, maintains buy rating on the stock

Given its healthy financial track record, domestic focus and extensive network, Mankind is likely to continue doing well, Hemang Jani of Motilal Oswal believes.

Mankind Pharma surges 32% on debut despite market volatility

Brokerage firm Macquarie Research has given Mankind Pharma Ltd an outperform rating with a target price of Rs 1400 per share, indicating a potential upside of 29.6% from its issue price of Rs 1068 per share.

Mankind debuts with 'outperform' rating from Macquarie; stock gets a 30% uptick

Mankind Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations across acute and chronic therapeutic areas. It offers products under the brands of Nurokind, Telmikind, Manforce, Unwanted, Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Prega News, Dydroboon, Cefakind, Monticope, and Caldikind. The company was founded by Ramesh Chand Juneja in 1986 and is headquartered in New Delhi, India.

Watchers	64
52-Wk Low	1,242.00
52-Wk High	1,949.00

Market Cap	701.75B
Volume (M)	123,106.00
52-Wk High	1,949.00
52-Wk Low	1,242.00

Current Price	1,751.80
Prev Close	1,739.80
Open	1,749.00
Dividend Yield	N/A
50-Day Moving Average	1,808.56
Beta	-1.16
Avg. Volume	470,856.59
PE Ratio	N/A

52-Week High	1,949.00
52-Week Low	1,242.00
Market Capitalization	701.75B
EPS	N/A
Price to Book	9.44
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

MANKIND.NSE Mankind Pharma Ltd.

About

Feed

News

Fundamentals